Aura Biosciences, Inc.
AURAAura Biosciences, Inc. in brief
Aura Biosciences, Inc. is a listed company in the Biotechnology industry, based in Boston, Massachusetts, USA. Its market value was $666 M on 29 October 2026, which makes it the 11,324th largest listed company in the world and the 2,348th largest in the USA on this site. It employs about 113 people. Its shares trade under the symbol AURA (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Aura Biosciences, Inc.
We are a clinical-stage biotechnology company developing precision therapies to treat solid tumors designed to preserve organ function. Our lead candidate bel-sar is in late-stage clinical development for the treatment of patients with early choroidal melanoma (defined as small choroidal melanoma and/or indeterminate lesions) and is also in clinical development for other ocular oncology indications and bladder cancer.
There is significant unmet need for novel treatments for patients with choroidal melanoma, given the limitations of the current standard of care, or SoC, and patient reluctance to undergo radiotherapy in the form of either plaque brachytherapy or proton beam therapy, both highly-invasive therapies that result in significant vision loss, and potential legal blindness in the treated eye. Enucleation, or surgical removal of the affected eye, is another treatment option for patients with choroidal melanoma, in which patients lose all vision without the possibility of vision restoration. We are evaluating the safety and efficacy of bel-sar as a potential vision-sparing therapy in our ongoing global Phase 3 CoMpass trial for the first-line treatment of adult patients with early choroidal melanoma. Moreover, we intend to assess the safety and efficacy of bel-sar in treating a range of other solid tumors, beginning with metastases to the choroid and bladder cancer where bel-sar is in clinical development, as well as in cancers of the ocular surface. We believe bel-sar, if approved, has the potential to change the current treatment paradigm for patients with ocular and urologic cancers and other solid tumors.
From the company's annual report filed with the US SEC: read the report
Aura Biosciences, Inc. timeline
- 2010
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2021
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 1 November 2021; shares registered for exchange trading on 26 October 2021.
Events of Aura Biosciences, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,290 (Jan 2022) · #2,834 (Dec 2022) · #2,800 (Jul 2023) · #2,643 (Jan 2024) · #1,425 (Mar 2026) · #2,238 (Aug 2026) · #2,357 (Oct 2026) · #2,350 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 4.9×
- Free cash flow yield
- -12.8%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -77.6%
- Liabilities / assets
- 19.2%
- Profit per employee
- $-940 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-113M | $-106M | — |
| Dec 2024 | — | — | $-96M | $-87M | — |
| Dec 2023 | — | — | $-85M | $-76M | — |
| Dec 2022 | — | — | $-60M | $-59M | — |
| Dec 2021 | — | — | $-35M | $-35M | — |
| Dec 2020 | — | — | $-22M | $-22M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-85M | $0M | $-85M | $-1.76 | — |
| Dec 2024 | $-80M | $1M | $-81M | $-1.75 | — |
| Dec 2023 | $-64M | $1M | $-65M | $-1.93 | — |
| Dec 2022 | $-55M | $1M | $-56M | $-1.96 | — |
| Dec 2021 | $-32M | $2M | $-35M | $-8.95 | — |
| Dec 2020 | $-24M | $1M | $-25M | $-82.06 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-32M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations · Other events
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-KCurrent reportResults of operations · Restructuring costs · Directors or officers changed · Other events
- Aug 5, 20268-KCurrent reportShareholder vote
- Jul 8, 20268-KCurrent reportDirectors or officers changed
- Jun 29, 2026DEF 14AProxy statement
- Jun 11, 20268-KCurrent reportShareholder vote
- May 11, 202610-QQuarterly report · period to Mar 2026
- May 11, 20268-KCurrent reportResults of operations · Other events
- May 5, 20268-KCurrent reportMaterial agreement
- May 4, 20268-KCurrent reportMaterial agreement · Results of operations · Other events
Official filings of Aura Biosciences, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-113 M
- Net income
- $-106 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $169 M
- Total liabilities
- $33 M
- Total equity
- $137 M
As of December-2025
Top 100 institutional investors in Aura Biosciences, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | TCG Crossover Management, LLC | 10,165,357 | +632,024 (+6.63%) | 9.77% | $64 M | Nov 16, 2026 |
| 2 | Frazier Life Sciences Management, L.P. | 7,100,000 | 0 (0.00%) | 6.82% | $45 M | Nov 16, 2026 |
| 3 | BlackRock, Inc. | 5,424,264 | +716,590 (+15.22%) | 5.21% | $34 M | Nov 13, 2026 |
| 4 | ADAR1 Capital Management, LLC | 5,385,879 | +5,255,727 (+4038.15%) | 5.17% | $34 M | Nov 16, 2026 |
| 5 | Fcpm III Services B.V. | 5,248,841 | +1,195,066 (+29.48%) | 5.04% | $33 M | Nov 16, 2026 |
| 6 | Long Focus Capital Management, LLC | 5,119,582 | 0 (0.00%) | 4.92% | $32 M | Nov 16, 2026 |
| 7 | Adage Capital Partners GP, L.L.C. | 4,640,000 | 0 (0.00%) | 4.46% | $29 M | Nov 16, 2026 |
| 8 | Caligan Partners LP | 4,590,253 | +292,005 (+6.79%) | 4.41% | $29 M | Nov 16, 2026 |
| 9 | Vanguard Capital Management LLC | 3,952,319 | -148,023 (-3.61%) | 3.80% | $25 M | Nov 13, 2026 |
| 10 | Nantahala Capital Management, LLC | 3,807,300 | -2,094,760 (-35.49%) | 3.66% | $24 M | Nov 13, 2026 |
| 11 | Orbimed Advisors LLC | 3,333,333 | 0 (0.00%) | 3.20% | $21 M | Nov 16, 2026 |
| 12 | Medicxi Ventures Management (Jersey) Ltd | 3,039,892 | 0 (0.00%) | 2.92% | $19 M | Nov 2, 2026 |
| 13 | Janus Henderson Group Ltd. | 2,727,664 | — | 2.62% | $17 M | Nov 16, 2026 |
| 14 | Montanova Capital, LLC | 2,645,080 | -4,561,137 (-63.29%) | 2.54% | $17 M | Nov 16, 2026 |
| 15 | Ra Capital Management, L.P. | 2,500,000 | 0 (0.00%) | 2.40% | $16 M | Nov 16, 2026 |
| 16 | State Street Corp | 2,301,520 | +1,078,536 (+88.19%) | 2.21% | $14 M | Nov 12, 2026 |
| 17 | Franklin Templeton Inc | 2,082,287 | +9,561 (+0.46%) | 2.00% | $13 M | Nov 12, 2026 |
| 18 | Geode Capital Management, LLC | 1,944,737 | +190,016 (+10.83%) | 1.87% | $12 M | Nov 6, 2026 |
| 19 | EcoR1 Capital, LLC | 1,666,667 | 0 (0.00%) | 1.60% | $10 M | Nov 16, 2026 |
| 20 | Redmile Group, LLC | 1,552,479 | -114,188 (-6.85%) | 1.49% | $10 M | Nov 16, 2026 |
| 21 | Trails Edge Capital Partners, LP | 1,443,333 | 0 (0.00%) | 1.39% | $9 M | Nov 16, 2026 |
| 22 | Bellevue Group AG | 1,418,014 | +251,347 (+21.54%) | 1.36% | $9 M | Nov 16, 2026 |
| 23 | Foresite Capital Management VI LLC | 1,333,334 | 0 (0.00%) | 1.28% | $8 M | Nov 16, 2026 |
| 24 | Woodline Partners LP | 1,210,910 | +727 (+0.06%) | 1.16% | $8 M | Nov 16, 2026 |
| 25 | Balyasny Asset Management L.P. | 1,187,679 | -1,166,940 (-49.56%) | 1.14% | $7 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Vivo Capital, LLC | 1,166,667 | 0 (0.00%) | 1.12% | $7 M | Nov 13, 2026 |
| 27 | Acorn Capital Advisors, LLC | 1,025,349 | +96,272 (+10.36%) | 0.99% | $6 M | Nov 16, 2026 |
| 28 | Boothbay Fund Management, LLC | 945,785 | +39,429 (+4.35%) | 0.91% | $6 M | Nov 16, 2026 |
| 29 | Goldman Sachs Group Inc | 944,951 | +480,283 (+103.36%) | 0.91% | $6 M | Nov 16, 2026 |
| 30 | Vanguard Portfolio Management LLC | 942,724 | +71,382 (+8.19%) | 0.91% | $6 M | Nov 13, 2026 |
| 31 | Levin Capital Strategies, L.P. | 826,834 | -11,233 (-1.34%) | 0.79% | $5 M | Nov 2, 2026 |
| 32 | B Group, Inc. | 764,243 | 0 (0.00%) | 0.73% | $5 M | Nov 16, 2026 |
| 33 | Dimensional Fund Advisors LP | 708,950 | +90,059 (+14.55%) | 0.68% | $4 M | Nov 4, 2026 |
| 34 | Stempoint Capital LP | 647,406 | -66,874 (-9.36%) | 0.62% | $4 M | Nov 16, 2026 |
| 35 | Vanguard Fiduciary Trust Co | 633,162 | -4,042 (-0.63%) | 0.61% | $4 M | Nov 13, 2026 |
| 36 | Northern Trust Corp | 607,281 | +57,819 (+10.52%) | 0.58% | $4 M | Nov 16, 2026 |
| 37 | Regency Capital Management Inc.\DE | 533,068 | -7,327 (-1.36%) | 0.51% | $3 M | Nov 9, 2026 |
| 38 | FMR LLC | 383,995 | +128,664 (+50.39%) | 0.37% | $2 M | Nov 10, 2026 |
| 39 | D. E. Shaw & Co., Inc. | 329,298 | +261,893 (+388.54%) | 0.32% | $2 M | Nov 16, 2026 |
| 40 | Citadel Advisors LLC | 304,523 | +252,621 (+486.73%) | 0.29% | $2 M | Nov 16, 2026 |
| 41 | Qube Research & Technologies Ltd | 272,145 | +162,581 (+148.39%) | 0.26% | $2 M | Nov 13, 2026 |
| 42 | XTX Topco Ltd | 266,731 | +116,800 (+77.90%) | 0.26% | $2 M | Nov 16, 2026 |
| 43 | HRT Financial LP | 266,720 | New | 0.26% | $2 M | Nov 13, 2026 |
| 44 | Jump Financial, LLC | 218,933 | +145,933 (+199.91%) | 0.21% | $1 M | Nov 13, 2026 |
| 45 | Quantinno Capital Management LP | 216,918 | +86,262 (+66.02%) | 0.21% | $1 M | Nov 13, 2026 |
| 46 | Trexquant Investment LP | 212,632 | New | 0.20% | $1 M | Nov 16, 2026 |
| 47 | Charles Schwab Investment Management Inc | 199,688 | +36,532 (+22.39%) | 0.19% | $1 M | Nov 16, 2026 |
| 48 | Morgan Stanley | 196,808 | +22,116 (+12.66%) | 0.19% | $1 M | Nov 13, 2026 |
| 49 | Bank Of America Corp /de/ | 178,144 | +90,982 (+104.38%) | 0.17% | $1 M | Nov 16, 2026 |
| 50 | Y-Intercept (Hong Kong) Ltd | 174,121 | New | 0.17% | $1 M | Oct 16, 2026 |
| 51 | Point72 Asset Management, L.P. | 164,651 | +146,787 (+821.69%) | 0.16% | $1 M | Nov 16, 2026 |
| 52 | Wellington Management Group LLP | 158,937 | +26,815 (+20.30%) | 0.15% | $1 M | Nov 16, 2026 |
| 53 | BNP Paribas Financial Markets | 142,574 | +36,223 (+34.06%) | 0.14% | $1 M | Nov 12, 2026 |
| 54 | Price T Rowe Associates Inc /MD/ | 142,244 | -136,227 (-48.92%) | 0.14% | $1 M | Nov 16, 2026 |
| 55 | Renaissance Technologies LLC | 140,084 | -34,116 (-19.58%) | 0.13% | $1 M | Nov 12, 2026 |
| 56 | Bank of New York Mellon Corp | 138,056 | +19,463 (+16.41%) | 0.13% | $1 M | Nov 5, 2026 |
| 57 | Platinum Investment Management LTD | 111,865 | 0 (0.00%) | 0.11% | $1 M | Nov 16, 2026 |
| 58 | UBS Group AG | 102,919 | +33,689 (+48.66%) | 0.10% | $1 M | Nov 10, 2026 |
| 59 | Nuveen, LLC | 100,715 | +16,911 (+20.18%) | 0.10% | $1 M | Nov 10, 2026 |
| 60 | Squarepoint Ops LLC | 96,342 | New | 0.09% | $1 M | Nov 9, 2026 |
| 61 | Algert Global LLC | 89,980 | New | 0.09% | $1 M | Nov 17, 2026 |
| 62 | Fisher Asset Management, LLC | 83,508 | 0 (0.00%) | 0.08% | $1 M | Nov 6, 2026 |
| 63 | Verdad Advisers, LP | 75,934 | New | 0.07% | $0 M | Nov 16, 2026 |
| 64 | Water Island Capital LLC | 72,500 | +12,500 (+20.83%) | 0.07% | $0 M | Nov 13, 2026 |
| 65 | Martingale Asset Management L P | 71,258 | 0 (0.00%) | 0.07% | $0 M | Nov 12, 2026 |
| 66 | Rhumbline Advisers | 63,492 | -165 (-0.26%) | 0.06% | $0 M | Nov 10, 2026 |
| 67 | Invesco Ltd. | 63,107 | +18,257 (+40.71%) | 0.06% | $0 M | Nov 12, 2026 |
| 68 | TBH Global Asset Management, LLC | 60,322 | 0 (0.00%) | 0.06% | $0 M | Nov 3, 2026 |
| 69 | American Century Companies Inc | 54,717 | New | 0.05% | $0 M | Nov 12, 2026 |
| 70 | Russell Investments Group, Ltd. | 54,618 | +36,628 (+203.60%) | 0.05% | $0 M | Nov 6, 2026 |
| 71 | AQR Capital Management LLC | 53,085 | -56,804 (-51.69%) | 0.05% | $0 M | Nov 16, 2026 |
| 72 | Deutsche Bank AG\ | 49,682 | +7,838 (+18.73%) | 0.05% | $0 M | Nov 6, 2026 |
| 73 | Magnetar Financial LLC | 49,584 | New | 0.05% | $0 M | Nov 13, 2026 |
| 74 | Virtus Investment Advisers, LLC | 49,506 | -1,539 (-3.01%) | 0.05% | $0 M | Nov 12, 2026 |
| 75 | Alliancebernstein L.P. | 48,390 | -4,370 (-8.28%) | 0.05% | $0 M | Nov 16, 2026 |
| 76 | Ameriprise Financial Inc | 42,682 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 77 | Rafferty Asset Management, LLC | 40,722 | New | 0.04% | $0 M | Nov 13, 2026 |
| 78 | Entropy Technologies, LP | 38,473 | New | 0.04% | $0 M | Nov 13, 2026 |
| 79 | Jane Street Group, LLC | 38,336 | New | 0.04% | $0 M | Nov 12, 2026 |
| 80 | Vanguard Global Advisers, LLC | 37,961 | +279 (+0.74%) | 0.04% | $0 M | Nov 13, 2026 |
| 81 | Jpmorgan Chase & Co | 36,123 | +8,741 (+31.92%) | 0.03% | $0 M | Nov 12, 2026 |
| 82 | Fox Run Management, L.L.C. | 35,700 | New | 0.03% | $0 M | Nov 12, 2026 |
| 83 | MetLife Investment Management, LLC | 34,208 | +8,988 (+35.64%) | 0.03% | $0 M | Nov 16, 2026 |
| 84 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 30,936 | +10,273 (+49.72%) | 0.03% | $0 M | Nov 16, 2026 |
| 85 | Los Angeles Capital Management LLC | 30,620 | +29,800 (+3634.15%) | 0.03% | $0 M | Nov 12, 2026 |
| 86 | Susquehanna International Group, LLP | 30,401 | New | 0.03% | $0 M | Nov 16, 2026 |
| 87 | Commonwealth Equity Services, LLC | 30,120 | -196 (-0.65%) | 0.03% | $0 M | Nov 2, 2026 |
| 88 | China Universal Asset Management Co., Ltd. | 29,722 | +5,168 (+21.05%) | 0.03% | $0 M | Oct 28, 2026 |
| 89 | Barclays PLC | 29,169 | +14,707 (+101.69%) | 0.03% | $0 M | Nov 6, 2026 |
| 90 | Letko, Brosseau & Associates Inc | 28,300 | 0 (0.00%) | 0.03% | $0 M | Nov 6, 2026 |
| 91 | Mercer Global Advisors Inc /adv | 27,102 | +15,662 (+136.91%) | 0.03% | $0 M | Nov 16, 2026 |
| 92 | Schonfeld Strategic Advisors LLC | 26,388 | New | 0.03% | $0 M | Nov 16, 2026 |
| 93 | Creative Planning | 26,189 | +10,717 (+69.27%) | 0.03% | $0 M | Nov 2, 2026 |
| 94 | Jain Global LLC | 24,289 | -6,311 (-20.62%) | 0.02% | $0 M | Nov 16, 2026 |
| 95 | Canada Pension Plan Investment Board | 22,400 | -4,600 (-17.04%) | 0.02% | $0 M | Nov 16, 2026 |
| 96 | Citigroup Inc | 20,934 | -2,498 (-10.66%) | 0.02% | $0 M | Nov 4, 2026 |
| 97 | Wealth Enhancement Advisory Services, LLC | 19,130 | +1,190 (+6.63%) | 0.02% | $0 M | Oct 13, 2026 |
| 98 | Inscription Capital, LLC | 18,610 | +804 (+4.52%) | 0.02% | $0 M | Nov 2, 2026 |
| 99 | Manufacturers Life Insurance Company, The | 18,098 | -17,940 (-49.78%) | 0.02% | $0 M | Nov 13, 2026 |
| 100 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 18,083 | +13,566 (+300.33%) | 0.02% | $0 M | Nov 16, 2026 |
Mutual funds holding Aura Biosciences, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 2.90 M | $21 M | 2.8% | <0.01% | +87% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.17 M | $8 M | 1.1% | 0.01% | +8.7% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 1.11 M | $8 M | 1.1% | <0.01% | +75% | Jun 30, 2026 |
| 🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc. | 765,617 | $5 M | 0.74% | 0.46% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 502,397 | $4 M | 0.48% | <0.01% | +67% | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 488,920 | $3 M | 0.47% | 0.01% | +10% | Jul 31, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 455,972 | $3 M | 0.44% | 0.04% | +35% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 394,396 | $3 M | 0.38% | 0.02% | +241% | Jun 30, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 279,337 | $2 M | 0.27% | 0.01% | +114% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 231,086 | $2 M | 0.22% | <0.01% | +6.5% | May 31, 2026 |
| 🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC | 196,067 | $1 M | 0.19% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 183,089 | $1 M | 0.18% | <0.01% | +49% | May 31, 2026 |
| 🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc. | 187,048 | $1 M | 0.18% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 181,359 | $1 M | 0.17% | <0.01% | +168% | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 174,907 | $1 M | 0.17% | <0.01% | −4.9% | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 146,935 | $1 M | 0.14% | <0.01% | +85% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 150,841 | $1 M | 0.14% | 0.07% | +33% | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 142,403 | $1 M | 0.14% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 109,878 | $1 M | 0.11% | 0.01% | +13% | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc. | 98,144 | $1 M | 0.09% | <0.01% | −56% | Jun 30, 2026 |
| 🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc. | 95,416 | $1 M | 0.09% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 81,616 | $1 M | 0.08% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 78,923 | $1 M | 0.08% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 59,882 | $0 M | 0.06% | 0.01% | +23% | Jul 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 58,464 | $0 M | 0.06% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 57,210 | $0 M | 0.05% | <0.01% | +83% | Jul 31, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 52,569 | $0 M | 0.05% | 0.06% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 47,184 | $0 M | 0.05% | <0.01% | +35% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 48,316 | $0 M | 0.05% | <0.01% | +63% | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 46,294 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 41,934 | $0 M | 0.04% | <0.01% | +50% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 39,732 | $0 M | 0.04% | <0.01% | −84% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 39,316 | $0 M | 0.04% | 0.02% | +256% | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 37,282 | $0 M | 0.04% | <0.01% | −19% | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 36,153 | $0 M | 0.03% | <0.01% | +83% | Jul 31, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 35,850 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 27,400 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 24,909 | $0 M | 0.02% | 0.01% | +13% | May 31, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 25,900 | $0 M | 0.02% | <0.01% | +27% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 23,276 | $0 M | 0.02% | 0.01% | +2.5% | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 22,361 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 21,330 | $0 M | 0.02% | <0.01% | +35% | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 21,415 | $0 M | 0.02% | 0.01% | +11% | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 16,436 | $0 M | 0.02% | <0.01% | −17% | May 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 16,886 | $0 M | 0.02% | <0.01% | +90% | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 15,800 | $0 M | 0.02% | <0.01% | −25% | Jun 30, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 15,697 | $0 M | 0.02% | <0.01% | +124% | Jul 31, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 14,960 | $0 M | 0.01% | 0.02% | +74% | Jul 31, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 14,689 | $0 M | 0.01% | 0.03% | −3.9% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 13,936 | $0 M | 0.01% | <0.01% | +3.0% | May 31, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 14,609 | $0 M | 0.01% | <0.01% | −4.4% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 14,498 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 12,495 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 AST PGIM Aggressive Multi-Asset PortfolioAST Investment Services, Inc. | 12,300 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 10,494 | $0 M | 0.01% | 0.01% | +24% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 10,059 | $0 M | <0.01% | 0.03% | +22% | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 9,919 | $0 M | <0.01% | <0.01% | +23% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc. | 9,908 | $0 M | <0.01% | <0.01% | −51% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 9,200 | $0 M | <0.01% | <0.01% | −15% | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP | 8,911 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 8,730 | $0 M | <0.01% | <0.01% | −0.8% | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 7,466 | $0 M | <0.01% | <0.01% | +46% | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 6,844 | $0 M | <0.01% | <0.01% | +40% | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 6,875 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 6,642 | $0 M | <0.01% | 0.01% | +22% | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 6,587 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 6,291 | $0 M | <0.01% | <0.01% | +225% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 6,112 | $0 M | <0.01% | <0.01% | −30% | Jun 30, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 6,105 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP | 5,875 | $0 M | <0.01% | <0.01% | +38% | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 5,714 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC | 5,147 | $0 M | <0.01% | 0.01% | −51% | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 4,945 | $0 M | <0.01% | <0.01% | +10% | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 4,736 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 4,544 | $0 M | <0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 4,287 | $0 M | <0.01% | 0.01% | +34% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 4,128 | $0 M | <0.01% | <0.01% | −89% | Jun 30, 2026 |
| 🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP | 4,130 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc. | 4,010 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 3,743 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 3,779 | $0 M | <0.01% | 0.02% | +312% | Jun 30, 2026 |
| 🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC | 3,602 | $0 M | <0.01% | 0.01% | −51% | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 3,623 | $0 M | <0.01% | <0.01% | +240% | Jul 31, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 3,364 | $0 M | <0.01% | 0.01% | +12% | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 3,252 | $0 M | <0.01% | <0.01% | −12% | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 3,190 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional US Vector Equity ETFDimensional Fund Advisors LP | 3,128 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP | 2,600 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 2,362 | $0 M | <0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 2,200 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 2,314 | $0 M | <0.01% | <0.01% | −25% | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 2,317 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Invesco Russell 2000 Dynamic Multifactor ETFInvesco Capital Management LLC | 2,151 | $0 M | <0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 2,243 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 2,119 | $0 M | <0.01% | <0.01% | +11% | May 31, 2026 |
| 🇺🇸 PGIM Balanced FundPrudential Investment Portfolios, Inc. | 2,100 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 2,107 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC | 1,795 | $0 M | <0.01% | <0.01% | −5.2% | May 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 1,676 | $0 M | <0.01% | <0.01% | −38% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 1,657 | $0 M | <0.01% | <0.01% | −39% | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Aura Biosciences, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Janet Jill HopkinsChief Medical Officer | Sell | -16,903 | $7.050 | $119 K | 363,287 | Form 4 |
| filed | Amy ElazzouziSVP, Finance & PAO | Grant or award | +23,540 | — | — | 143,600 | Form 4 |
| filed | Julie PersonChief People Officer | Grant or award | +107,611 | — | — | 107,611 | Form 4 |
| filed | Susan Abu-AbsiChief Operating Officer | Grant or award | +134,513 | — | — | 134,513 | Form 4 |
| filed | Janet Jill HopkinsChief Medical Officer | Grant or award | +58,850 | — | — | 380,190 | Form 4 |
| filed | Erica KratzChief Reg. & Quality Officer | Grant or award | +100,885 | — | — | 100,885 | Form 4 |
| filed | Jeremy BenderDirector | Grant or award | +30,000 | — | — | 30,000 | Form 4 |
| filed | Conor KilroySee Remarks | Grant or award | +14,858 | — | — | 232,693 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Aura Biosciences, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-13.7 reverse split
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q3 2026 | Q3 2026 | $0M |
| Q3 2025 | Q3 2026 | $0M |
Fails to deliver
- : 2,243 shares at $6.40
- : 275 shares at $6.18
- : 690 shares at $6.46
- : 73 shares at $6.10
- : 4,015 shares at $6.17
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Aura Biosciences, Inc. scorecard#
Passes 1 of the 12 checks that could be worked out. Fiscal year 2025; market cap of Oct 29, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median4.9×Price to book 4.9× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-12.8%Free cash flow is -12.8% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.76 vs -1.75Diluted EPS -1.76 in fiscal 2025 against -1.75 the year before (report's currency).
- ✗Net income higher than five years earlier-$106 M-$106 M in fiscal 2025 against -$22 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$106 MNet income -$106 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-73.5%-73.5% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities8.2×Current ratio 8.15 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year21.5%Diluted shares up 21.5% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Aura Biosciences, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Research and development | 90+23.2%— | 73+12.4%— | 65+54.4%— | 42+67.9%— | 25+39.5%— | 18—— | |
| General and administrative | 22−1.4%— | 23+15.5%— | 20+9.4%— | 18+79.0%— | 10+142%— | 4.2—— | |
| Operating income | −113—— | −96—— | −85—— | −60—— | −35—— | −22—— | |
| Other non-operating income (expense) | 6.7−27.9%— | 9.3+6.8%— | 8.7+469%— | 1.5—— | −0.0—— | — | |
| Income before tax | −106—— | −87—— | −76—— | −59—— | — | — | |
| Income tax | 0.1−3.6%— | 0.1−18.2%— | 0.1—— | 0—— | 0—— | 0—— | |
| Net income including minority interests | −106—— | −87—— | −76—— | −59—— | −35—— | −22—— | |
| Net income attributable to shareholders | −106—— | −87—— | −76—— | −59—— | −35—— | −22—— | |
| Earnings per share, basic | -1.76—— | -1.75—— | -1.93—— | -1.96—— | -8.95—— | -82.06—— | |
| Earnings per share, diluted | -1.76—— | -1.75—— | -1.93—— | -1.96—— | -8.95—— | -82.06—— | |
| Shares, weighted average (basic) | 60+21.5%— | 50+25.3%— | 40+32.3%— | 30+480%— | 5.2—— | — | |
| Shares, weighted average (diluted) | 60+21.5%— | 50+25.3%— | 40+32.3%— | 30+480%— | 5.2+1305%— | 0.4—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 60+87.8%35.1% | 32−22.8%17.4% | 41−66.2%16.1% | 122−18.4%54.3% | 149+757%93.1% | 17—78.7% | |
| Other current assets | 0.7r1.2−63.9%0.4% | 1.8−24.2%1.0% | 2.4+237%0.9% | 0.7r0.7+983%0.3% | 0.1+313%0.0% | 0.0—0.1% | |
| Current assets | 150−6.8%88.4% | 161−30.7%88.0% | 232+17.8%90.9% | 197+28.0%87.8% | 154+733%96.0% | 18—83.5% | |
| Property, plant and equipment | 2.6−18.4%1.5% | 3.2+2.1%1.8% | 3.2−41.4%1.2% | 5.4+2.3%2.4% | 5.3+46.9%3.3% | 3.6—16.2% | |
| Right-of-use (leased) assets | 16−8.9%9.3% | 17−7.8%9.5% | 19−8.8%7.4% | 21+2076%9.2% | 1.0—0.6% | — | |
| Total assets | 169−7.2%100% | 183−28.5%100% | 255+13.9%100% | 224+39.9%100% | 160+624%100% | 22—100% | |
| Accounts payable | 1.5−32.8%0.9% | 2.3+28.9%1.3% | 1.8−38.8%0.7% | 2.9+21.7%1.3% | 2.4+293%1.5% | 0.6—2.8% | |
| Current liabilities | 18+23.3%10.8% | 15+20.7%8.2% | 12+18.2%4.8% | 10+42.2%4.7% | 7.4r7.3+176%4.6% | 2.7—12.0% | |
| Lease liabilities (non-current) | 14−9.5%8.3% | 16−7.4%8.6% | 17−5.7%6.6% | 18+4871%8.0% | 0.4—0.2% | — | |
| Total liabilities | 33+6.5%19.2% | 31+4.5%16.7% | 29+3.1%11.5% | 28+267%12.7% | 7.7+181%4.8% | 2.7—12.4% | |
| Retained earnings | −480—−284% | −374—−205% | −287—−113% | −211—−94.2% | −152—−95.1% | −117—−529% | |
| Shareholders' equity | 137−9.9%80.8% | 152−32.7%83.3% | 226+15.5%88.5% | 196+28.4%87.3% | 152—95.2% | −109—−492% | |
| Total liabilities and equity | 169−7.2%100% | 183−28.5%100% | 255+13.9%100% | 224+39.9%100% | 160+624%100% | 22—100% | |
| Shares outstanding | 64+27.2%— | 50+1.3%— | 49+30.7%— | 38+29.3%— | 29+7565%— | 0.4—— | |
| Cash-flow statement | |||||||
| Share-based compensation | 14+22.1%— | 12+33.6%— | 8.8+36.8%— | 6.4+178%— | 2.3+213%— | 0.7—— | |
| Cash from operating activities | −85—— | −80—— | −64—— | −55—— | −32—— | −24—— | |
| Capital expenditure | −0.4—— | −1.3—— | −0.7—— | −1.1—— | −2.1—— | −0.8—— | |
| Cash from investing activities | 36−48.3%— | 69—— | −114—— | −68—— | −2.1—— | −0.8—— | |
| Shares issued | 47—— | 0—— | — | 87+10.1%— | 79—— | — | |
| Cash from financing activities | 77+4737%— | 1.6−98.4%— | 97+1.7%— | 96−42.5%— | 166+1557%— | 10—— | |
| Change in cash | — | −9.4—— | −81—— | −27−120%— | 132—— | −15—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 105+16.1%— | 25+11.6%— | 31+34.4%— | 28+19.8%— | 22*−2.0%— | 22+30.2%— | 23+35.6%— | 23+36.9%— | 22*+10.1%— | 17—— | 17—— | 17—— | 20*—— | |
| General and administrative | 40+76.3%— | 10+80.2%— | 17+202%— | 6.9+21.3%— | 5.3*−2.4%— | 5.7−7.6%— | 5.7−2.6%— | 5.7+8.2%— | 5.5*+21.5%— | 6.2—— | 5.9—— | 5.3—— | 4.5*—— | |
| Operating income | −145—— | −35—— | −48—— | −35—— | −27*—— | −28—— | −29—— | −29—— | −28*—— | −23—— | −23—— | −22—— | −25*—— | |
| Other non-operating income (expense) | 8.4+19.5%— | 3.0+68.4%— | 2.5+49.9%— | 1.2−24.1%— | 1.7*−15.2%— | 1.8−19.3%— | 1.6−32.3%— | 1.6−40.8%— | 2.0*−28.4%— | 2.2—— | 2.4—— | 2.7—— | 2.8*—— | |
| Income before tax | −137—— | −32—— | −46—— | −34—— | −26*—— | −26—— | −27—— | −27—— | −26*—— | −21—— | −20—— | −20—— | −22*—— | |
| Income tax | 0.1−19.8%— | 0.0+46.2%— | 0.0−39.6%— | 0.0−38.9%— | 0.0*−37.5%— | 0.0−39.5%— | 0.0—— | 0.0−60.9%— | 0.0*−82.5%— | 0.0—— | 0*—— | 0.0—— | 0.1*—— | |
| Net income including minority interests | −137—— | −32*—— | −46*—— | −34—— | −26*—— | −26*—— | −27*—— | −27—— | −26*—— | −21*—— | −20*—— | −20—— | −22*—— | |
| Net income attributable to shareholders | −137—— | −32—— | −46—— | −34—— | −26*—— | −26—— | −27—— | −27—— | −26*—— | −21—— | −20—— | −20—— | −22*—— | |
| Earnings per share, basic | — | -0.29—— | -0.48—— | -0.50—— | — | -0.40—— | -0.47—— | -0.55—— | — | -0.42—— | -0.41—— | -0.40—— | — | |
| Earnings per share, diluted | — | -0.29—— | -0.48—— | -0.50—— | — | -0.40—— | -0.47—— | -0.55—— | — | -0.42—— | -0.41—— | -0.40—— | — | |
| Shares, weighted average (basic) | 111+68.5%— | 111+68.5%— | 95+63.5%— | 67+34.6%— | — | 66+32.8%— | 58+17.1%— | 50+1.4%— | — | 50—— | 50—— | 49—— | — | |
| Shares, weighted average (diluted) | 111+68.5%— | 111+68.5%— | 95+63.5%— | 67+34.6%— | — | 66+32.8%— | 58+17.1%— | 50+1.4%— | — | 50—— | 50—— | 49—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 42—13.0% | 42−12.4%13.0% | 68−36.8%19.5% | 85+122%61.6% | 60+87.8%35.1% | 48+87.2%25.0% | 107+257%52.5% | 38+45.5%24.6% | 32−22.8%17.4% | 25—12.4% | 30—13.8% | 26—11.2% | 41—16.1% | |
| Other current assets | 0.9—0.3% | 0.9−67.1%0.3% | 0.8−68.7%0.2% | 1.1−40.1%0.8% | 0.7r1.2−63.9%0.4% | 2.6−24.4%1.4% | 2.6+5.8%1.3% | 1.8−22.6%1.1% | 1.8−24.2%1.0% | 3.4—1.7% | 2.5—1.1% | 2.3—1.0% | 2.4—0.9% | |
| Current assets | 303—94.2% | 303+78.2%94.2% | 329+78.9%94.5% | 119−11.9%86.1% | 150−6.8%88.4% | 170−7.3%89.5% | 184−6.0%90.0% | 135−36.6%86.6% | 161−30.7%88.0% | 183—89.4% | 196—89.6% | 212—90.3% | 232—90.9% | |
| Property, plant and equipment | 2.0—0.6% | 2.0−23.0%0.6% | 2.2−23.1%0.6% | 2.5−20.5%1.8% | 2.6−18.4%1.5% | 2.6−20.9%1.4% | 2.9−14.1%1.4% | 3.1+1.9%2.0% | 3.2+2.1%1.8% | 3.3—1.6% | 3.3—1.5% | 3.1—1.3% | 3.2—1.2% | |
| Right-of-use (leased) assets | 15—4.5% | 15−10.3%4.5% | 15−9.8%4.3% | 15−9.3%11.2% | 16−8.9%9.3% | 16−8.5%8.5% | 17−8.4%8.1% | 17−8.1%10.9% | 17−7.8%9.5% | 18—8.6% | 18—8.3% | 19—7.9% | 19—7.4% | |
| Total assets | 322—100% | 322+69.3%100% | 348+70.3%100% | 138−11.4%100% | 169−7.2%100% | 190−7.5%100% | 204−6.4%100% | 155−33.9%100% | 183−28.5%100% | 205—100% | 218—100% | 235—100% | 255—100% | |
| Accounts payable | 1.7—0.5% | 1.7−8.8%0.5% | 2.3+75.3%0.6% | 2.6+28.3%1.9% | 1.5−32.8%0.9% | 1.9−5.2%1.0% | 1.3−11.9%0.6% | 2.0+3.8%1.3% | 2.3+28.9%1.3% | 2.0—1.0% | 1.5—0.7% | 1.9—0.8% | 1.8—0.7% | |
| Current liabilities | 21—6.6% | 21+13.4%6.6% | 20+31.7%5.6% | 17+37.4%12.1% | 18+23.3%10.8% | 19+27.9%9.9% | 15+40.8%7.3% | 12+25.9%7.8% | 15+20.7%8.2% | 15—7.2% | 11—4.8% | 9.7—4.1% | 12—4.8% | |
| Lease liabilities (non-current) | 13—4.0% | 13−11.6%4.0% | 13−10.8%3.8% | 14−10.1%10.0% | 14−9.5%8.3% | 15−8.9%7.6% | 15−8.4%7.3% | 15−7.9%9.8% | 16−7.4%8.6% | 16—7.8% | 16—7.5% | 17—7.1% | 17—6.6% | |
| Total liabilities | 34—10.6% | 34+2.5%10.6% | 33+10.4%9.4% | 30+10.9%22.1% | 33+6.5%19.2% | 33+8.8%17.6% | 30+11.0%14.6% | 27+4.5%17.7% | 31+4.5%16.7% | 31—14.9% | 27—12.3% | 26—11.2% | 29—11.5% | |
| Retained earnings | −592—−184% | −592—−184% | −560—−161% | −514—−373% | −480—−284% | −455—−239% | −429—−210% | −402—−258% | −374—−205% | −348—−170% | −327—−150% | −307—−131% | −287—−113% | |
| Shareholders' equity | 287—89.4% | 287+83.5%89.4% | 315+80.5%90.6% | 107−16.2%77.9% | 137−9.9%80.8% | 157−10.3%82.4% | 175−8.8%85.4% | 128−38.7%82.3% | 152−32.7%83.3% | 175—85.1% | 191—87.7% | 209—88.8% | 226—88.5% | |
| Total liabilities and equity | 322—100% | 322+69.3%100% | 348+70.3%100% | 138−11.4%100% | 169−7.2%100% | 190−7.5%100% | 204−6.4%100% | 155−33.9%100% | 183−28.5%100% | 205—100% | 218—100% | 235—100% | 255—100% | |
| Shares outstanding | 104—— | 104+65.0%— | 103+66.7%— | 64+27.7%— | 64+27.2%— | 63+26.5%— | 62+25.2%— | 50+1.5%— | 50+1.3%— | 50—— | 50—— | 50—— | 49—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 24+74.6%— | 4.9+33.5%— | 12+223%— | 3.8+8.8%— | 3.3*+11.7%— | 3.7+34.1%— | 3.8+22.6%— | 3.5+20.8%— | 2.9*+12.8%— | 2.8—— | 3.1—— | 2.9—— | 2.6*—— | |
| Cash from operating activities | −109—— | −26*—— | −33*—— | −30—— | −20*—— | −20*—— | −21*—— | −23—— | −24*—— | −15*—— | −16*—— | −24—— | −17*—— | |
| Capital expenditure | −0.4—— | −0.1*—— | −0.0*—— | −0.1—— | −0.2*—— | −0.0*—— | −0.0*—— | −0.2—— | −0.3*—— | −0.3*—— | −0.5*—— | −0.1—— | −0.3*—— | |
| Cash from investing activities | −141−498%— | 0.1*—— | −226*−1231%— | 55+84.1%— | 30*+0.4%— | −44*−545%— | 20*+0.7%— | 30+217%— | 30*—— | 9.9*—— | 20*—— | 9.4—— | −90*—— | |
| Shares issued | — | 0*—— | — | — | 0*—— | 0*—— | — | — | 0*—— | 0*—— | — | — | — | |
| Shares bought back | — | 0*—— | — | — | — | 0*—— | — | — | — | — | — | — | — | |
| Cash from financing activities | 245+227%— | 0.2*−95.3%— | 242*+246%— | 0.3+213%— | 2.8*+410%— | 4.4*+509%— | 70*+84152%— | 0.1−62.1%— | 0.5*−99.4%— | 0.7*—— | 0.1*—— | 0.3—— | 93*—— | |
| Change in cash | — | — | — | — | — | — | — | — | 6.3*—— | −4.7*—— | 3.8*—— | −15—— | −15*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Aura Biosciences, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Restructuring 1 · Directors and officers 6 · Material agreement 3 · Bylaws or fiscal year changed 1 · Shareholder vote 4 · Results announced 12
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| RestructuringDirectors and officersResults announced | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Material agreementResults announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Directors and officersResults announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Acquisitions and funding#
9 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2021 | $80 M | No. 9 | $50 to $250 million | 41 | equity | SEC |
| Jun 2020 | $10 M | No. 8 | $10 to $50 million | 32 | equity | SEC |
| Apr 2019 | $20 M | No. 7 | $10 to $50 million | 36 | equity | SEC |
| Dec 2017 | $42 M | No. 6 | $10 to $50 million | 42 | equity | SEC |
| Sep 2016 | $12 M | No. 5 | $10 to $50 million | 38 | debt, options | SEC |
| Feb 2015 | $21 M | No. 4 | $10 to $50 million | 21 | equity, options | SEC |
| Apr 2014 | $4 M | No. 3 | $2 to $10 million | 41 | equity | SEC |
| Aug 2012 | $3 M | No. 2 | $2 to $10 million | 22 | equity | SEC |
| May 2011 | $3 M | No. 1 | $2 to $10 million | 23 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Aura Biosciences, Inc.#
3 labor condition applications certified in fiscal 2025 for 3 positions, at a median wage of $170 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior Manager, QA, GXP OperationsQuality Control Systems Managers | 2 | $170 K |
| Senior ScientistBiochemists and Biophysicists | 1 | $161 K |
Where: Monmouth Junction, NJ 2 · Boston, MA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2025 | 3 | 3 | $170 K | 3 |
| FY2024 | 1 | 1 | $165 K | 1 |
| FY2023 | 1 | 1 | $190 K | 1 |
| FY2022 | 2 | 2 | $175 K | 2 |
| FY2021 | 1 | 1 | $100 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Aura Biosciences, Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 20% of workforce | Restructuring planSEC 8-K | “As part of the Realignment, the Company plans to reduce its workforce by approximately 20%.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
Discuss Aura Biosciences, Inc.#
2 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 9 November 2026automatic update · Nov 9, 2026
Aura Biosciences, Inc. announced results on 9 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $32 million.
- Mutual funds: 116 funds hold $81 millionautomatic update · Jul 31, 2026
116 mutual funds in 1 country hold shares of Aura Biosciences, Inc. worth $81 million, about 10.8% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 55 funds added shares and 24 sold; on balance they bought $24 million. Share splits are not counted as trading.
How Aura Biosciences, Inc. compares in Biotechnology
- Market cap$666 M · higher than 62% of 726
- Price / book4.9× · lower than 32% of 534
- FCF yield-12.8% · higher than 52% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Aura Biosciences, Inc.🇺🇸 | $666 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Lexicon Pharmaceuticals, Inc.$659 M
- Immix Biopharma, Inc.$675 M
- Candel Therapeutics, Inc.$679 M
- CorMedix Inc.$652 M
- AgomAb Therapeutics NV$651 M
- Arbutus Biopharma Corporation$644 M
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of February 28, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Aura Biosciences, Inc.? Verify and update this profile — free
Show Aura Biosciences, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.